Compare Flux Power Holdings Inc (FLUX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Sanofi SA — how do they compare? Flux Power Holdings Inc trades at $0.68 (market cap $15.37M), while Sanofi SA trades at $43.67 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 6762.5× Flux Power Holdings Inc's market cap, and Sanofi SA pays a 5.54% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | SNY | |
|---|---|---|
Market Cap | $15.37M | $103.94B |
Sector | Utilities | Health |
52-Week High | $6.66 | $52.34 |
52-Week Low | $0.71 | $41.33 |
Enterprise Value | $21.53M | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.689, down 3.85% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $6.67 million in 2025 and a negative net income margin of -12.48% in 2026, though revenue remains substantial. Recent news highlights product innovation with the launch of SkyEMS 3.0 and new executive appointments aimed at growth. Analyst consensus is unanimously bullish with 6 buy ratings.
The outlook is mixed: strong analyst support and strategic developments offer upside potential, but persistent losses and bearish technicals pose significant risks. Investors must weigh growth initiatives against profitability challenges and market volatility.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
